Abstract
Three different classes of aryl hydroxamic acid scaffolds have been explored and provided potent inhibitors of MMP-1, -2, -9, -13 and TACE. Structure-based design has allowed the evolution of these inhibitors from broad spectrum inhibitors into compounds that are more selective for MMPs relevant to particular disease states. Aryl hydroxamates selective for MMP-9, MMP-13 and TACE have been disclosed that may aid in the study of the physiological role of these enzymes. Furthermore, the different selectivity profiles offered by these MMP / TACE inhibitors may allow the determination of which metalloprotease, or group of metalloproteases, must be inhibited for the safe, long-term treatment of osteoarthritis, rheumatoid arthritis and cancer. Some of these compounds have demonstrated useful biological activity in efficacy models relevant to osteoarthritis and rheumatoid arthritis and are therefore potential clinical candidates.
Keywords: aryl hydroxamic acids, aryl hydroxamates, mmp inhibitor, tace inhibitor, anthranilic acid
Current Topics in Medicinal Chemistry
Title: The Design and Synthesis of Aryl Hydroxamic Acid Inhibitors of MMPs and TACE
Volume: 4 Issue: 12
Author(s): Jeremy I. Levin
Affiliation:
Keywords: aryl hydroxamic acids, aryl hydroxamates, mmp inhibitor, tace inhibitor, anthranilic acid
Abstract: Three different classes of aryl hydroxamic acid scaffolds have been explored and provided potent inhibitors of MMP-1, -2, -9, -13 and TACE. Structure-based design has allowed the evolution of these inhibitors from broad spectrum inhibitors into compounds that are more selective for MMPs relevant to particular disease states. Aryl hydroxamates selective for MMP-9, MMP-13 and TACE have been disclosed that may aid in the study of the physiological role of these enzymes. Furthermore, the different selectivity profiles offered by these MMP / TACE inhibitors may allow the determination of which metalloprotease, or group of metalloproteases, must be inhibited for the safe, long-term treatment of osteoarthritis, rheumatoid arthritis and cancer. Some of these compounds have demonstrated useful biological activity in efficacy models relevant to osteoarthritis and rheumatoid arthritis and are therefore potential clinical candidates.
Export Options
About this article
Cite this article as:
Levin I. Jeremy, The Design and Synthesis of Aryl Hydroxamic Acid Inhibitors of MMPs and TACE, Current Topics in Medicinal Chemistry 2004; 4 (12) . https://dx.doi.org/10.2174/1568026043387935
DOI https://dx.doi.org/10.2174/1568026043387935 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Tankyrase as a Novel Molecular Target in Cancer and Fibrotic Diseases
Current Drug Targets Taking Risk Prediction to the Next Level. Advances in Biomarker Research for Atherosclerosis
Current Pharmaceutical Design Associations between Periodontitis and Systemic Inflammatory Diseases: Response to Treatment
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) The Purinome, a Complex Mix of Drug and Toxicity Targets
Current Topics in Medicinal Chemistry Capillaroscopic Findings in Primary Fibromyalgia
Current Rheumatology Reviews The Application of Freidinger Lactams and their Analogs in the Design of Conformationally Constrained Peptidomimetics
Current Medicinal Chemistry Development of New Drugs for COPD
Current Medicinal Chemistry Radiosynthesis of 8-Fluoro-3-(4-[18F]Fluorophenyl)-3,4-Dihydro-1-Isoquinolinamine ([18F]FFDI), a Potential PET Radiotracer for the Inducible Nitric Oxide Synthase
Current Radiopharmaceuticals Small Molecule Inhibitors of NF-κB and JAK/STAT Signal Transduction Pathways as Promising Anti-Inflammatory Therapeutics
Mini-Reviews in Medicinal Chemistry Perspectives on the Use of Gene Therapy for Chronic Joint Diseases
Current Gene Therapy Proteoglycan Involvement in Inflammatory Diseases. New Developments in GAG-Based Therapies
Medicinal Chemistry Reviews - Online (Discontinued) Allosteric Inhibitors of SHP2: An Updated Patent Review (2015-2020)
Current Medicinal Chemistry Ambiguities in Neutrophil Extracellular Traps. Ongoing Concepts and Potential Biomarkers for Rheumatoid Arthritis: A Narrative Review
Current Rheumatology Reviews 3D-QSAR Study on Ring Substituted Imidazoles for Their Antitubercular Activity
Letters in Drug Design & Discovery Cardioprotective Properties of HDL: Structural and Functional Considerations
Current Medicinal Chemistry Immunoadjunctive Therapy against Bacterial Infections Using Herbal Medicines Based on Th17 Cell-mediated Protective Immunity
Current Pharmaceutical Design Meet Our Editorial Board Member
Current Rheumatology Reviews Oxidative Stress in the Early Stage of Psychosis
Current Topics in Medicinal Chemistry Oxidative Stress in Autoimmune Diseases: An Under Dealt Malice
Current Protein & Peptide Science Hormone Replacement Therapy in Rheumatoid Arthritis
Current Rheumatology Reviews